Tech Bio

At Enveda, they are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. This platform harnesses nature's complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics. Enveda is starting a movement to create the next generation of small molecule therapeutics.

Tetratherix has developed a proprietary, fully synthetic biomaterial that is compatible with minimally invasive administration techniques and does not induce any foreign body reaction, a genuine biostealth platform technology. The company has active development programs in the areas of regenerative medicine and mRNA delivery. Our world-leading team has spent a decade, inventing and developing the biomaterial technology and has proven its safety and efficacy as the world’s first biostealth matrix.

RevoNA holds huge potential in treating currently ‘undruggable’ diseases by overcoming the challenges associated with targeting RNA. Conventional approaches are slow and costly, limited by inadequate R&D tools and RNA complexity, resulting in a shortage of crucial data in the field. Next-generation technologies are essential to unlocking the necessary data to drive RNA Drug discovery forward. RevoNA’s innovative solution integrates a novel high-throughput RNA biological platform, that rapidly amasses premium RNA datasets enriched with diverse information. These comprehensive datasets feed a complementary AI prediction engine build, that will enable RevoNA to significantly reduce the time-to-market for RNA-targeted drugs and make discovery affordable at scale.